Last reviewed · How we verify
Adalimumab-US
Tumor necrosis factor-alpha inhibitor
Tumor necrosis factor-alpha inhibitor Used for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis.
At a glance
| Generic name | Adalimumab-US |
|---|---|
| Sponsor | Pfizer |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 1 |
Mechanism of action
Adalimumab is a fully human monoclonal antibody that selectively binds to tumor necrosis factor-alpha (TNF-alpha) and inhibits its interaction with cell surface TNF receptors. This action prevents TNF-alpha from inducing inflammation and cell death.
Approved indications
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Crohn's Disease
- Ulcerative Colitis
Common side effects
- Injection site reaction
- Headache
- Fatigue
- Muscle pain
- Nausea
Key clinical trials
- A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
- To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects (PHASE1)
- A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
- A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
- Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab) (PHASE1)
- Adalimumab PK Bioequivalence Study to EU and US Sourced Humira (PHASE1)
- To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects (PHASE1)
- Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adalimumab-US CI brief — competitive landscape report
- Adalimumab-US updates RSS · CI watch RSS
- Pfizer portfolio CI